期刊文献+

新型重组人肿瘤坏死因子治疗非小细胞肺癌的多中心Ⅱ期临床随机试验 被引量:33

A multicenter randomized phase Ⅱ trial of domestic product of nrhTNF in the treatment of non-small cell lung cancer
下载PDF
导出
摘要 目的 观察比较国产新型重组人肿瘤坏死因子 (nrhTNF)加化疗和单纯化疗治疗非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法 采用多中心、随机对照试验将 90例NSCLC患者随机分为试验组和对照组 ,两组各 45例患者。试验组在化疗的同时 ,分别在第 1~ 7天 ,第 11~ 17天肌肉注射nrhTNF 4×10 6U/m2 ,2 1天为一周 ,连用二个周期。对照组仅给予化疗 ,2 1天为一周期 ,连用二个周期。试验结束后比较试验组和对照组的有效率和不良反应。结果 试验组和对照组各有 3例患者因依从性原因出组 ,各有 42例可供临床疗效分析和不良反应分析。试验组有效率为 47.62 % ( 2 0 /4 2 ) ,对照组为 19.0 5 % ( 8/4 2 ) (P =0 .0 0 2 )。试验组治疗后KPS评分为 85 .0 2± 10 .74,对照组为 81.3 5± 9.63 (P =0 .0 3 8)。试验组和对照组Ⅲ+Ⅳ度不良反应无显著差异 (P >0 .0 5 )。与nrhTNF有关的不良反应主要有轻度发热、感冒样症状 ,注射局部疼痛 ,注射局部红肿硬结 ,均不需作特殊处理 ,治疗结束后均能自行消失。结论 国产nrhTNF联合化疗药物治疗NSCLC能显著提高化疗的有效率 ,改善患者的生活质量。nrhTNF临床应用安全、有效 ,不良反应轻微 。 Objective To evaluate and compare the effects and toxicity of the domestic product of nrhTNF combined with chemotherapy in the trial group and chemotherapy alone in the control group in the treatment of patients with non small cell lung cancer (NSCLC). Methods Ninety patients with NSCLC in multicenter were randomly devided into trial group and control group. Each group had 45 patients. Chemotherapy with CAP regimen was given for the patients in the trial group. Meanwhile, nrhTNF injection of 4×10 6 U/m 2 was also given from the 1st to 7th days, the 11th to 17th days on the chemotherapy course. Twenty one days were as a cycle, 2 cycles were given each patients. Chemotherapy alone with CAP regimen was given in the control group. The chemothepeutic effects and toxicity were observed and compared between the two groups after the therapy. Results Of the 90 patients, 3 cases in each group were out of the trial because of economy. The other 84 cases (each group had 42 patients) could be used to analyze and evaluate the clinical effects and toxicity. The response rate of chemotherapy was 47.62% (20/42) in the trial group and 19.05% (8/42) in the control group (P=0.002) respectively. The KPS was 85.02±10.74 in the trial group, and 81.35±9.63 in the control group (P=0.038). No significant difference of degree Ⅲ+Ⅳ toxicity was observed between the trial group and control group (P>0.05). The side effects related to nrhTNF included slight fever, cold like symptoms, pain, and red and swelling in injection site. All of them were mild and didn't need any treatment and disappeared after the therapy. Conculsion The results demonstrate that the effects of domestic nrhTNF combined with chemotherapy can remarkably higher than that of chemotherapy alone in the treatment of NSCLC. It is able to increase the sensitivity to chemotherapy and improve the quality of life of the patients. The toxicity is also slight and is worth to expand clinical use, so as to further evaluate its effect and toxicity.
出处 《中国肺癌杂志》 CAS 2003年第1期42-45,共4页 Chinese Journal of Lung Cancer
关键词 新型重组人肿瘤坏死因子 治疗 非小细胞肺癌 肺肿瘤 联合化疗 随机对照试验 多中心试验 Lung neoplasms New recombinant human tumor necrosis factor Combined chemotherapy Phase Ⅱ clinical trial Randomly trial
  • 相关文献

参考文献7

  • 1[1]Lee KY, Chang W, Qiu D, et al. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem,1999,274(19)∶13451-13455. 被引量:1
  • 2[2]Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst,1996,88 (19)∶1383-1392. 被引量:1
  • 3[3]Lasek W, Giermasz A, Kuc K, et al. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results. Int J Cancer,1996,66(3)∶374-379. 被引量:1
  • 4黄敏丽,孙红,丰有吉,尹德领.肿瘤坏死因子及化疗联合治疗晚期妇科恶性肿瘤的探索[J].中国肿瘤生物治疗杂志,1995,2(3):201-203. 被引量:3
  • 5[5]Chcialowski A, Targowski T, Bajera I, et al. Tumor necrosis factor-alpha--phase Ⅰ and phase Ⅱ clinical trials. Pol Merkuriusz Lek,1997,2(12)∶396-399. 被引量:1
  • 6[6]Tomita A, Fuchino Y, Otsuka K, et al. Clinical effects of exogenous/endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients. Anticancer Res,1998,18(5D)∶3937-3939. 被引量:1
  • 7[7]Fukushima T, Yamamoto M, Ikeda K, et al. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Anticancer Res,1998,18(5D)∶3965-3970. 被引量:1

共引文献2

同被引文献167

引证文献33

二级引证文献146

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部